Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK3207 · 2 trials · 2 indications
Reduction of a Grade 2 or 3 severity migraine at baseline to Grade 0 at 2 hours postdose. Rating of Headache Severity (Scale from Grade 0 to 3): * Grade 0: No pain * Grade 1: Mild pain * Grade 2: Moderate pain * Grade 3: Severe pain
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | MK3207- 2.5 mg |
| 2 | EXPERIMENTAL | MK3207- 5 mg |
| 3 | EXPERIMENTAL | MK3207- 10 mg |
| 4 | EXPERIMENTAL | MK3207- 20 mg |
| 5 | EXPERIMENTAL | MK3207- 50 mg |
| 6 | EXPERIMENTAL | MK3207- 100 mg |
| 7 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| MK3207- 2.5 mg | DRUG | Arm 1: MK3207 2.5 mg taken after migraine onset. |
| MK3207- 5 mg | DRUG | Arm 2: MK3207 5 mg taken after migraine onset. |
| MK3207- 10 mg | DRUG | Arm 3: MK3207 10 mg taken after migraine onset. |
| MK3207- 20 mg | DRUG | Arm 4: MK3207 20 mg taken after migraine onset. |
| MK3207- 50 mg | DRUG | Arm 5: MK3207 50 mg taken after migraine onset. |
| MK3207- 100 mg | DRUG | Arm 6: MK3207 100 mg taken after migraine onset. |
| Comparator: placebo (unspecified) | DRUG | Placebo taken after migraine onset. |
| MK3207 | DRUG | M3207 (20 mg); patients will be administered a single dose of 100 mg of MK3207 (i.e., 5 x20-mg tablets). |
Inclusion Criteria: * Men and Women from 18 to 65 years of age * 1+ year history of migraine that typically last from 4 to 72 hours if untreated * Had from 2 to 8 moderate or severe migraine attacks per month in the last 2 months * Not pregnant or planning to become pregnant in next 6 months Exclu...
Top 5 of 8 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 13 | PHASE3 | Atogepant, Ubrogepant, MEDI0618 |
| Pfizer Inc. | PFE | 11 | PHASE3 | Rimegepant, Zavegepant |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Galcanezumab |
| Amgen Inc. | AMGN | 2 | PHASE3 | Erenumab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
MK3207 is being developed for the treatment of migraine and migraine disorders. It is a small molecule under study for acute migraine treatment, and the clinical program has focused on patients 18 years and older with migraine. It remains investigational and is not an approved therapy.
MK3207 targets CALCRL, the calcitonin receptor-like receptor, and acts as an antagonist. By blocking CALCRL, the drug is designed to interfere with CGRP-family signaling implicated in migraine. This mechanism places MK3207 in the same target class as other small molecule migraine therapies aimed at CGRP pathway receptors.
MK3207 is being developed by Merck & Company, Inc., which trades under the ticker MRK. Merck conducted the clinical studies of the compound in migraine, including a Phase 2 trial and an earlier Phase 1 study. The asset is an internal Merck program rather than a partnered or out-licensed candidate.
MK3207 is in Phase 2 development. The furthest advanced study is a completed Phase 2 trial in acute migraine, and the program has not progressed beyond that stage. MK3207 is investigational and has not been approved by the FDA for any indication.
MK3207 has been studied in two completed trials. NCT00712725 was a Phase 2 trial of MK3207 for treatment of acute migraines that enrolled 676 patients. NCT00548353 was a Phase 1 study of gastric delay in migraine patients that enrolled 22 participants. Both studies are listed as completed.